Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Uncategorized

INVESTOR CALENDER OF THE WEEK May 20,2025 To May 22,2025 RBC Capital Markets Global Healthcare Conference, Barclays European Leadership Conference, London 2025 Annual Meeting of Shareholders May 20 May 21 May 22 May 21 REGENERON GILEAD AMGEN AstraZeneca Thermo Fisher SCIENTIFIC Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for May 20–22. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for May 20–22. 💻 Read More »

VYUHPHARMA AbTherx CREATING CURES AbTherx and Spice Biotechnologies have launched a multi-program antibody discovery collaboration utilizing the Atlas™™ mouse platform AstraZeneca AstraZeneca's Trixeo Aerosphere has receiveed UK approval with a near-zero GWP propellant, achieving a 99.9% reduction in global warming impact for respiratory inhalers Roche The FDA has approved Roche's VENTANA MET assay, paving the way for the precise selection of NSCLC patients for AbbVie's EMRELIS (Collaboration, ADC, Phase 3) (UK, Approval, Sustainability) (FDA, Approval, NSQ-NSCLC) All logos and trademarks remain the intellectual properties of their respective owners

📢 Highlights from May 12 to 19 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from May 12 to 19 in the world of pharma and healthcare! 🗞️👀 Read More »

Bank of America Securities Healthcare Conference May 13 May 14 May 15 NOVARTIS Takeda Jazz Pharmaceuticals Thermo Fisher SCIENTIFIC GILEAD MERCK AMGEN REGENERON VIATRIS abbvie Q1 2025 Earnings Call Lilly May 12 May 13 May 15 GRIFOLS B A BAYER E ER MERCK Visit our website for more updates | www.vyuhpharma.com

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for May 12–15. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for May 12–15. 💻 Read More »

Vyuhpharma Alchemab (Collaboration) Alchemab licensed its ATLX-1282 program to Eli Lilly, with Alchemab lead early Phase 1 trials and Lilly will handle further development and commercialization GRIN Therapeutics (EMA, CHMP Opinion, Orphan designation) EMA CHMP granted a positive orphan designation for GRIN Therapeutics radiprodil, following its recent PRIME status from EMA and Breakthrough Therapy and Orphan Drug designations from the FDA GeneFab (Collaboration, Clinical Manufacturing, Auto immune disease) GeneFab partnered with RegCell to support the US clinical manufacturing of RegCell's Treg therapies for autoimmune diseases Genezen (Collaboration, CAR-T therapy) Genezen and Optieum Biotechnologies form strategic partnership to advance cGMP manufacturing of OPTF01, a next-generation CAR-T therapy targeting glioblastoma Mersana (Layoff, R&D) Mersana restructures to extend runway, prioritize Emi-Le in breast cancer; 55% workforce cut is expected by Q3 2025 ProBioGen (Collaboration, Cell line, Biosimilar) ProBioGen and Polpharma Biologics partner for cell line development to advance biosimilar pipeline, supporting the expansion of their growing

📢 Highlights from May 05 to 09 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from May 05 to 09 in the world of pharma and healthcare! 🗞️👀 Read More »

INVESTOR CALENDER OF THE WEEK May 05,2025 To May 09,2025 01 2025 EARNINGS CONFERENCE CALL May 05 May 06 VERTEX Jazz Pharmaceuticals May 08 May 09 VIATRIS Lonza GILEAD 2025 Annual Meeting of Shareholders May 06 Bristol Myers Squibb May 07 Berenberg R&D Leaders: Back to the Future May 08 Roche Uploaded on: May 5, 2025 Uploaded by: Bachili kallappa N File name: Calander-May-20250505.jpg File type: image/jpeg File size: 78 KB Dimensions: 960 by 540 pixels Alternative Text AstraZeneca 2

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for May 05–09. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for May 05–09. 💻 Read More »

VYUHPHARMA (Clinical data, Phase 3) NEUROCRINE BIOSCIENCES Neurocrine Biosciences advances NBI-III7568 into Phase 3 as a potential treatment for adults with schizophrenia Henlius (Collaboration, commercialization) Henlius secures upfront $31M in Sandoz deal for HLX13 biosimilar, aiming to expand access in immuno-oncology SYNHALE THERAPEUTER Synhale Therapeutics expands pipeline with telaglenastat acquisition, advancing into Phase 2 for pulmonary hypertension (Acquisition) (FDA, NDA) novo nordisk Novo Nordisk's oral semaglutide 25 mg accepted for FDA review as first potential oral GLP-1 therapy for obesity All logos and trademarks remain the intellectual properties of their respective owners

📢 Highlights from April 28 to May 02 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from April 28 to May 02 in the world of pharma and healthcare! 🗞️👀 Read More »

VYUHPHARMA Akesobio Akeso's ivonescimab combined with chemotherapy, shows statistically significant and positive Phase 3 results in the first-line treatment of sq-NSCLC compared to tislelizumab with chemotherapy (Clinical data, Phase 3) REPERTOIRE R Repertoire Immune Medicines has partnered with Genentech to develop T cell-targeted immune therapies for autoimmune diseases using the DECODE platform DAAN DAAN Biotherapeutics has signed an exclusive licensing agreement with GC Cell for a tumor antigen-specific antibody sequence in CAR-T and CAR-NK therapy development (collaboration) (Agreement) All logos and trademarks remain the intellectual properties of their respective owners

📢 Highlights from April 21 to 25 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from April 21 to 25 in the world of pharma and healthcare! 🗞️👀 Read More »

Q1 2025 Earnings Call April 28,2025 To May 02,2025 April 29 April 30 Pfizer NOVARTIS GSK Biogen Biogen BAUSCH Health AstraZeneca REGENERON Otsuka dorsia May 01 AMGEN Alkermes moderna Lilly ORGANON Visit our website for more updates | www.vyuhpharma.com

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 28–May 01. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 28–May 01. 💻 Read More »

Vyuhpharma Celltrion (FDA, Phase 3) Celltrion's YUFLYMA receives FDA interchangeable designation, supported by positive Phase 3 study data for moderate-to-severe plaque psoriasis Wayfinder Bioscinces + Daiichi Sankyo (Collaboration) "Wayfinder and Daiichi Sankyo have announced an R&D collaboration in neurodegeneration Eli Lilly (Clinical data, Phase 3) Lilly's oral GLP-1, orforglipron, has met its primary endpoints in a Phase 3 trial, demonstrating significant efficacy and safety comparable to injectable GLP-1 therapies Sanofi + Earendil Labs (Agreement) "Earendil Labs and Sanofi have entered into a license agreement for two potential first-in-class bispecific atibodies, HXN-1002 and HXN-1003, targeting autoimmune and inflammatory bowel diseases All logos and trademarks remain the intellectual properties of their respective owners

📢 Highlights from April 14 to 18 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from April 14 to 18 in the world of pharma and healthcare! 🗞️👀 Read More »

INVESTOR CALENDER OF THE WEEK Q1 2025 Earnings Call Annual Meeting of Shareholders Annual General Meeting April 23 April 24 April 25 Thermo Fisher SCIENTIFIC Pfizer MERCK April 24 Roche MERCK CHAINSA April 25 Bristol Myers Squibb sanofi GILEAD B A BAYER ER April 25 abbvie Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 21–25. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 21–25. 💻 Read More »

← Previous 1 … 10 11 12 … 14 Next →

Search

Recent Posts

Highlights from the Week of 22nd June – 29th June in the world of pharma and healthcare!
Highlights from the Week of 15th June – 22nd June in the world of pharma and healthcare!
Today, June 21, is World ALS Day. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, impairing a person’s ability to move, speak, and breathe. Raising awareness isn’t just about acknowledging the disease; it’s about advocating for better care, funding critical research, and fostering inclusive communities. Let’s use our platforms today to amplify the voices of those living with ALS/MND and support the scientists working tirelessly toward a cure. 💡
Shining a light on World Sickle Cell Day. Today, we stand in solidarity with the millions of individuals globally managing sickle cell disease. Raising awareness is just the first step—driving equitable access to healthcare, advancing clinical research, and fostering inclusive environments are where real change happens. Let’s commit to being a part of the solution. 🩸❤️
Today, our team stands in solidarity with the global community on World Kidney Cancer Day. Renal Cell Carcinoma (RCC) impacts hundreds of thousands of families worldwide every year.”Awareness is the first line of defense. By amplifying the conversation around Renal Cell Carcinoma, we empower individuals to take charge of their health before it’s too late.”This year, our emphasis is on supporting the emotional well-being of patients and caregivers bearing the psychological burden of this disease. Let’s break the silence, encourage proactive health check-ups, and foster a more supportive environment for everyone affected by kidney cancer.🧡 Check in on your loved ones, prioritize your metabolic health, and let’s spread awareness together.

Recent Comments

No comments to show.

Archives

June 2026
May 2026
April 2026
March 2026
February 2026
January 2026
December 2025
November 2025
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
April 2025
March 2025
February 2025
January 2025

Categories

Uncategorized

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message